Align Tech Wins China Patent Case: RMB 10M Damages, Halt of Angelalign Products

For medical device companies operating in China, intellectual property protection has long been a double-edged sword. Now, Align Technology’s first-instance court victory against Angelalign signals that Chinese courts are willing to enforce foreign-owned patents against domestic competitors, potentially reshaping the competitive landscape in the rapidly growing clear-aligner market.

On August 10, 2026, the Jinan Intermediate People’s Court in China delivered a first-instance judgment holding that Angelalign Technology’s MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system infringed Align Technology’s extraction-gap-closure patent (CN113693748B). The court ordered Angelalign to immediately cease using the patented technology, stop manufacturing and selling the infringing aligner products, and pay RMB 10 million (approximately $1.4 million) in damages. This ruling is the latest and most impactful salvo in a widening global intellectual-property campaign by Align, the maker of the Invisalign system, against its main Chinese rival. The decision follows a February 2026 preliminary injunction from the Unified Patent Court (UPC) requiring Angelalign to halt infringement of Align’s ClinCheck Live Update technology—a ruling later upheld on appeal—and a July 2026 complaint filed with the U.S. International Trade Commission (ITC) seeking to bar imports of Angelalign products into the United States.

“

The court ordered Angelalign to immediately cease using the patented technology, stop manufacturing and selling the infringing aligner products, and pay RMB 10 million (approximately $1.4 million) in damages.

The patent at issue, CN113693748B, covers technology that plans and executes orthodontic treatment to close extraction gaps—a clinically critical step in complex clear-aligner cases. Angelalign’s MasterForce and ATreat software platforms generate premolar extraction treatment solutions (specifically, the A7 and A7 Speed product families) that the Chinese court found to copy Align’s protected method. This technical overlap means Angelalign cannot simply redesign a hardware component; it must overhaul the algorithmic core of its treatment-planning software, a deeply integrated capability that differentiates modern clear-aligner companies. For Align, which holds over 3,000 patents worldwide and has invested decades in digital orthodontics, the ruling validates its core IP in the world’s largest orthodontic market by volume.

The victory carries significant market implications. China’s clear-aligner market is projected to grow at a compounded 20% annually, driven by rising disposable income and expanding access to dental care. Angelalign, a domestic champion listed on the Hong Kong Stock Exchange, has rapidly gained share by undercutting Align on price and leveraging local distribution. The injunctive order could force Angelalign to suspend sales of key products in its home market, eroding revenue momentum and potentially benefiting Align’s Invisalign system. However, the relatively modest damage award—RMB 10 million compared with Angelalign’s annual revenue of over RMB 1.5 billion—suggests the court focused on halting future infringement rather than imposing punitive sanctions. Moreover, Angelalign may still appeal the judgment to the Supreme People’s Court, a process that could delay enforcement for months or years.